We previously reported that the effect of HLA-DRB1*04:05 on MS patients differed between northern and southern Japan13; therefore, we additionally compared MS patients from northern and southern Japan with and without HLA-DRB1*04:05 (Supplementary Tables S2, S3). Here, HLA-DRB1 is linked to myeloid sarcoma.